• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-05-06

  This study introduces a zwitterionic peptide amphiphile engineered for dual enzyme responsiveness, achieving unprecedented cancer cell selectivity via intralysosomal self-assembly. The approach leverages differential enzyme expression to induce selective cancer cell death, with significant implications for the design of targeted peptide therapeutics.

• 3-Bromopyruvate and Cetuximab: Ferroptosis to Overcome CRC R

  2026-05-05

  Mu et al. reveal that co-treatment with 3-bromopyruvate and cetuximab surmounts intrinsic and acquired resistance in colorectal cancer cells by triggering autophagy-dependent ferroptosis. Mechanistic dissection identifies FOXO3a pathway activation as central to this effect, presenting a translational strategy for refractory CRC.

• Optimizing DNA Synthesis: Advanced Insights on the 10 mM dNT

  2026-05-05

  Explore the molecular science behind the 10 mM dNTP mixture and its critical role in high-fidelity DNA synthesis. This article provides advanced, evidence-based guidance and reveals new mechanistic insights that set it apart from standard PCR reagent discussions.

• Clarithromycin as a CYP3A Inhibitor: Precision Tools for Pre

  2026-05-04

  Explore the advanced, protocol-focused use of Clarithromycin as a CYP3A inhibitor in drug-drug interaction research. Discover how detailed molecular properties, rigorous assay parameters, and strategic reference insights enable exceptional predictability and reproducibility in pharmacokinetic studies.

• Gramine Induces Ferroptosis via CUL3–MTDH Axis in TNBC Model

  2026-05-04

  This study demonstrates that Gramine, a natural indole alkaloid, suppresses triple-negative breast cancer by inducing ferroptosis through CUL3-mediated ubiquitination of MTDH. The findings reveal a novel pathway for ferroptosis regulation and highlight Gramine’s translational potential as a precision tool in cancer biology research.

• CTCF Maintains Centromere Function and Mitotic Fidelity

  2026-05-03

  This study demonstrates that CTCF is essential for maintaining centromere integrity, accurate chromosome alignment, and mitotic fidelity. Rapid depletion of CTCF disrupts centromere architecture, increasing mitotic errors and altering nuclear morphology, with important implications for cancer research.

• Polyploid Giant Cancer Macrophages as Blood Biomarkers of Tu

  2026-05-02

  This study elucidates the clinical and biological relevance of circulating polyploid giant cancer macrophages (CAMLs), demonstrating their strong correlation with disease progression across multiple solid tumor types. The findings refine the understanding of metastatic niche initiation and provide a compelling rationale for targeting the underlying cellular signaling pathways in translational oncology.

• Plk1-Mediated Phosphorylation Regulates p31comet in MCC Disa

  2026-05-02

  This study elucidates how Polo-like kinase 1 (Plk1) directly regulates the activity of p31comet in mitotic checkpoint complex (MCC) disassembly via phosphorylation. The findings clarify molecular details of checkpoint inactivation, offering new insights for cell cycle research and experimental design.

• Flubendazole: Precision Autophagy Modulation in Breast Cance

  2026-05-01

  This thought-leadership article explores how Flubendazole, a benzimidazole-derived autophagy activator from APExBIO, is transforming translational oncology. We synthesize recent mechanistic insights—especially the role of TAM-derived EVs and miR-660 in breast cancer metastasis—with strategic guidance for researchers leveraging autophagy signaling pathways. By contrasting APExBIO’s Flubendazole with other autophagy modulators, we highlight the unique advantages for reproducible experimental design and discuss the compound’s relevance in dissecting tumor–immune interactions, thereby setting a forward-looking agenda for next-generation cancer biology research.

• Reliable Cell Assays with Poly(I:C), a Synthetic dsRNA Analo

  2026-04-30

  This article addresses persistent laboratory challenges in cell viability, proliferation, and cytotoxicity assays by showcasing the validated performance of Poly(I:C), a synthetic double-stranded RNA (dsRNA) analog and Toll-like receptor 3 (TLR3) agonist (SKU B5551). Drawing on quantitative evidence and scenario-driven Q&A, the discussion guides biomedical researchers in optimizing innate immune response stimulation and dendritic cell maturation workflows with APExBIO’s Poly(I:C).

• Epalrestat as a Metabolic Modulator: Beyond Diabetic Models

  2026-04-30

  Explore Epalrestat’s role as an aldose reductase inhibitor not only in diabetic neuropathy research but also as a strategic tool for dissecting cancer metabolism and oxidative stress. This article uniquely connects polyol pathway inhibition to practical decisions in advanced disease modeling.

• Ampicillin Sodium: Mechanism, Benchmarks & Workflow Integrat

  2026-04-29

  Ampicillin sodium is a β-lactam antibiotic that acts as a competitive transpeptidase inhibitor, disrupting bacterial cell wall biosynthesis and exhibiting potent antibacterial activity. This article details its molecular mechanism, quantitative efficacy, and best practices for research workflows. APExBIO’s high-purity Ampicillin sodium supports reproducible results in antibacterial activity assays and recombinant protein applications.

• Fulvestrant (ICI 182,780): Beyond ER Antagonism in Breast Ca

  2026-04-29

  Discover how Fulvestrant (ICI 182,780) advances research in ER-positive breast cancer by enabling post-translational MDM2 regulation and immune modulation. This in-depth review explores novel mechanistic insights and practical assay decision points, setting it apart from standard protocol guides.

• Oligomycin A as a Mitochondrial ATP Synthase Inhibitor: Prec

  2026-04-28

  Oligomycin A delivers unmatched specificity for dissecting mitochondrial ATP production and metabolic adaptation, empowering advanced workflows in cancer metabolism and apoptosis pathway studies. This article details optimized protocols, troubleshooting strategies, and the translational edge provided by APExBIO’s Oligomycin A in high-impact mitochondrial research.

• Capture-and-Release Strategy Boosts LFA Sensitivity via Ampl

  2026-04-28

  This study introduces the AmpliFold capture-and-release workflow, significantly enhancing the sensitivity of lateral flow assays (LFAs) through triggered rebinding mechanisms. The approach leverages cleavable linkers and optimized bioconjugation to overcome traditional kinetic limitations, offering up to 16-fold sensitivity improvements and practical advances for point-of-care testing.

16210 records 1/1081 page Next 12345 下5页 Last page